Structure via PubChem · Public domain (PubChem)
doxapram
Sign in to saveAlso known as AHR-619, Dopram®, (+-)-doxapram, 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone, (+-)-Doxapram, 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone, Doxapramum
Doxapram is a respiratory stimulant, or analeptic. Administered intravenously, doxapram stimulates an increase in tidal volume, and respiratory rate.
Chemical data
- Formula
- C24H30N2O2
- Molecular weight
- 378.5 g/mol
- IUPAC name
- 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one
- SMILES
- CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4
- InChIKey
- XFDJYSQDBULQSI-UHFFFAOYSA-N
- XLogP
- 3.3
- Polar surface area
- 32.8 Ų
- H-bond donors
- 0
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Research
698 papers- Doxapram for the prevention and treatment of apnea in preterm infants.The Cochrane database of systematic reviews · 2023
- Doxapram Treatment for Apnea of Prematurity: A Systematic Review.Neonatology · 2017
- Not the classical serendipity: does doxapram treat atrial fibrillation?Cardiovascular research · 2022
- Doxapram treatment for apnea in preterm infants.The Cochrane database of systematic reviews · 2004
- Doxapram.Lancet (London, England) · 1973
via PubMed
Wikidata facts
- Mass
- 378.231
Show 5 more facts
- chemical formula
- C₂₄H₃₀N₂O₂
- canonical SMILES
- CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4
- World Health Organisation international non-proprietary name
- doxapram
- defined daily dose
- 0.4
- Commons category
- Doxapram
via Wikidata · CC0
~2 min read
Article
6 sectionsContents
- Medical uses
- Side effects
- Mechanism of action
- Appearance
- See also
- References
Doxapram is a respiratory stimulant, or analeptic. Administered intravenously, doxapram stimulates an increase in tidal volume, and respiratory rate.
==Medical uses== Doxapram is used in intensive care settings to stimulate the respiratory rate in patients with respiratory failure. It may be useful for treating respiratory depression in patients who have taken excessive doses of drugs such as opioids which may fail to respond adequately to treatment with naloxone.